¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦ 52ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°è±¹Á¦Çмú´ëȸ : 2020-08-07

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦ 52ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°è±¹Á¦Çмú´ëȸ : 2020-08-07
±³À°ÀÏÀÚ : 2020-08-07
±³À°Àå¼Ò : ºÎ»ê, º¤½ºÄÚ(Á¦2Àü½ÃÀå)  
±³À°ÁÖÁ¦ : Á¦ 52ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°è±¹Á¦Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : Á¤º°
¿¬¶ôó : 02-565-3350  
À̸ÞÀÏ : ksh@koreanhypertension.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, ½Å°æ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ¾à¸®ÇÐ, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 22 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø(6¸¸¿ø),Á¤È¸¿ø ¿Ü(8¸¸¿ø), Àü°øÀǹױâŸ(4¸¸¿ø), °£È£»ç/¿µ¾ç»ç/¾à»ç(2¸¸¿ø), Çлý-´ëÇÑ¿ø»ý Á¦¿Ü/º¸°Ç´ë/°£È£´ë/ÀÇ´ë(¹«·á)/65¼¼ ÀÌ»ó Á¤È¸¿ø(¹«·á) *ÇöÀåµî·Ï:ȸ¿ø(8¸¸¿ø),ºñȸ¿ø(10¸¸¿ø), Àü°øÀǹױâŸ(5¸¸¿ø), °£È£»ç/¿µ¾ç»ç/¾à»ç(2¸¸¿ø), Çлý-´ëÇпø»ý Á¦¿Ü/º¸°Ç´ë/°£È£´ë/ÀÇ´ë(¹«·á)/65¼¼ ÀÌ»ó Á¤È¸¿ø(¹«·á)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-07 Room A 09:00~10:00 Role of the 3rd generation beta-blockers in the future treatment for hypertension  Á¶±¸¿µ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 09:00~09:15 Recent Guidelines on Lifestyle Modifications  ±èÈ¿Àº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 09:15~09:30 Dietary Behavior to Prevent and Treatment Hypertension  ±èº´±Ô(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 09:30~09:45 Individual Exercise Strategy for Lowering Blood Pressure  ¹ÚÁ¤ÁØ(ºÎ»ê´ëÇб³) 
±³À°½Ã°£ 08-07 Room C 09:45~10:00 Obesity Correction Effects According to Hypertension Stage  ±è±âÇö(¿ï»êÀÇ´ë) 
Åä·Ð 08-07 Room C 10:00~10:10 Panel Discussion  Á¤Çý¹®, Çã¶õ(°æÈñÀÇ´ë, ÇѾçÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 10:30~10:45 Blood Pressure and Kidney Donor (Nephrectomy)  ±è¼öÇö(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 10:45~11:00 Blood Pressure and Kidney Transplant Recipient  ¼Û»óÇå(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 11:00~11:15 Blood Pressure and Valvular Heart Disease (Natural Prognosis)  ¼­Áö¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 11:15~11:30 Blood Pressure and Valve Surgery (OP Outcome)  ±è´ëÈñ(¿ï»êÀÇ´ë) 
Åä·Ð 08-07 Room A 11:30~11:40 Panel Discussion  ±è¹Ì³ª, ±è¹Î°ü, ±èÇüÀ±(°í·ÁÀÇ´ë, ¿¬¼¼ÀÇ´ë, Àü³²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 10:30~10:45 Glycemic Effect of GLP-1 RA and Review of Recent Guideline Focused on GLP- 1RA  ±ÇÇõ»ó(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 10:45~11:00 Impact of GLP-1 RA on Blood Pressure  ÀÌÈñ¼±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 11:00~11:15 Cardiovascular Effect and Potential Mechanism of Reducing Cardiovascular Mortality of GLP-1 RA  Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 11:15~11:30 Microvascular Outcomes of GLP-1RA (or rRenal Effect of GLP-1 RA)  Á¤Àΰæ(°æÈñÀÇ´ë) 
Åä·Ð 08-07 Room B 11:30~11:40 Panel Discussion  ±è¹Ì³ª, ±è¹Î°ü, ±èÇüÀ±(°í·ÁÀÇ´ë, ¿¬¼¼ÀÇ´ë, Àü³²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 10:30~10:45 Ambulatory Blood Pressure Monitoring in Heart Failure Patients [Eng]  ±è°æÁø(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 10:45~11:00 Ambulatory Blood Pressure Monitoring in Stroke Patients [Eng]  ±è¹üÁØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 11:00~11:15 Ambulatory Blood Pressure Monitoring in Chronic Kidney Disease Patients [Eng]  Â÷¶õÈñ(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 08-07 Room C 11:15~11:30 Ambulatory Blood Pressure Monitoring in Diabetes or Autonomic Dysfunction [Eng]  Yuqing Zhang(China) 
Åä·Ð 08-07 Room C 11:30~11:40 Panel Discussion  ¹Ú°æÀÏ, ÀÌÁ¤Ç¥, Á¶ÁØȯ(µ¿¾ÆÀÇ´ë, ¼­¿ïÀÇ´ë, Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 11:40~12:00 Approaches for the Medical Management of Resistant Hypertension  ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 12:00~12:20 What is your choice for CV risk reduction? (Aspirin or Statin)  ¹÷°æÀÏ(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 11:40~12:00 Clinical Considerations for Use of ARB+CLD Combination Therapy in Hypertension  ±è±¤ÀÏ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 12:00~12:20 Angiotensin Receptor Blocker Based Blood Pressure Control in Hypertensive patients with Left Ventricular Hypertrophy  ¹®Á¤±Ù(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 11:40~12:00 The Trend of New Technology of Cardiovascular Field Silicon Valley [Eng]  Fumiaki lkeno(Stanford University, US) 
±³À°½Ã°£ 08-07 Room C 12:00~12:20 The Emerging Era of Wearable Cuffless Blood Pressure Monitors [Eng]  George Stergiou(Greece reorge(Greece) 
±³À°½Ã°£ 08-07 Room C 12:20~12:30 The Role of Monitoring Ambulatory Central Blood Pressure [Eng]  Á¶ÀºÁÖ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 12:30~12:40 The Role of Monitoring of Home Blood Pressure [Eng]  Á¶µ¿Çõ(¿¬¼¼¿øÁÖÀÇ´ë) 
Åä·Ð 08-07 Room C 12:40~12:50 Panel Discussion  Á¶Á¤¼±, ¹Ú»ó¹Î, ±è°æÁø(°¡Å縯ÀÇ´ë, À»ÁöÀÇ´ë, ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 12:50~13:05 Recent Prevalence of High Risk Pregnant Women  ¹Ú¼º¹Ì(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 13:05~13:20 What Kinds of Problem Can Hypertension Cause during Pregnancy?  À̵¿Çü(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 13:20~13:35 Current Status of Anti-Hypertensive Drug Availability for Pregnant Women in Korea  ½ÅÁøÈ£(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 13:35~13:50 Practical Approach for Perinatal BP Control  ¹Ú¼ºÇÏ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 08-07 Room A 13:50~14:05 Panel Discussion  À̹ÎÈ£, Á¶ÁØȯ, ÃÖÁ¤Çö(¼øõÇâÀÇ´ë, Áß¾ÓÀÇ´ë, ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 12:50~13:05 Importance of Risk Factor Variability in Disease Prediction  ±èÇöâ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 13:05~13:20 Statistical Approach for Assessing BP Variability  ±èµ¿¿í(±¹¹Î°Ç°­º¸Çè°ø´Ü) 
±³À°½Ã°£ 08-07 Room B 13:20~13:35 Machine Learning Approach for Assessing BP variability  ¾È¼ºº¹(ÀÌÈ­¿©´ëÀ¶ÇÕº¸°ÇÇаú) 
±³À°½Ã°£ 08-07 Room B 13:35~13:50 Analysis of Long-term BP Variability with Real World Data  °­´ë¿ë(¿¬¼¼¿øÁÖÀÇ´ë) 
Åä·Ð 08-07 Room B 13:50~14:05 Panel Discussion  ±æÈ«·®, ¹éÀç¼÷, Á¶µ¿Çõ(Ãæ³²ÀÇ´ë, ¿ï»êÀÇ´ë, ¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 12:50~13:05 How to Manage for Resistant Hypertension in Pregnancy [Eng]  Á¶ÀºÁÖ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 13:05~13:20 Baroreflex Stimulation for Treating Resistant Hypertension [Eng]  ±è¹Ì³ª(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 13:20~13:35 Exercise as a Tool for Resistant Hypertension Management: Current Insights [Eng]  ÃÖÁøÈ£(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 13:35~13:50 Novel Catheter-based Renal Denervation System of Cryoablation (Cryo-RDN) for Resistant Hypertension [Eng]  Junbo Ge(China) 
Åä·Ð 08-07 Room C 13:50~14:05 Panel Discussion  ±è¼ÛÀÌ, Á¶ÀÎÁ¤(Á¦ÁÖÀÇ´ë, ÀÌÈ­ÀÇ´ë) 
È޽Ġ08-07  14:05~14:30 Moderated poster with coffee break  () 
±³À°½Ã°£ 08-07 Room A 14:35~15:05 Comprehensive management of hypertension in high risk patients  ±è±¤ÀÏ(¼­¿ïÀÇ´ë) 
Åä·Ð 08-07 Room A 15:05~15:30 Discussion  () 
±³À°½Ã°£ 08-07 Room B 14:30~15:00 From ASCOT to ASCOT Legacy: the Long-term Benefit for CV Patients.  ¾çÇö¼÷(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 15:00~15:30 What could be optimal strategy to treat HTN & DYS in DM patients  ±è¹Ì°æ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 14:30~14:45 Epidemiology and Pathophysiology of Sleep Apnea  À±ÇöÁÖ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 14:45~15:00 Cardiovascular Events: Focused on Resistant Hypertension  ¹Ú»ó¹Î(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 15:00~15:15 15 Interpretation of Polysomnography  Á¶±Ô¼·(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 15:15~15:30 Management of Patients with Sleep Apnea  ±èµ¿±Ô(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 15:30~15:45 Updates in Therapeutic Approach of Atherosclerosis  ¹Ú¿µ¹Ì(ÀÌÈ­¿©´ë) 
±³À°½Ã°£ 08-07 Room A 15:45~16:00 Role of Inflammation and Immunity in Hypertension  ±èÀΰâ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 16:00~16:15 Redox Regulation of Vascular Inflammation  Àüº´È­(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 16:15~16:30 Renal Fibrosis in Alport Syndrome  ¹èÀºÈñ(Àü³²ÀÇ´ë) 
Åä·Ð 08-07 Room A 16:30~16:45 Panel Discussion  Â÷´ë·æ(°æÈñÀÇ´ë, °í·ÁÀÇ´ë, Ãæ³²ÀÇ´ë, °í·ÁÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 15:30~15:45 Brain-Heart Axis: Cerebrogenic Cardiomyopathy  ¼­¿ì±Ù(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 15:45~16:00 Hypertension and Cerebral Artery Dissection/Aneurysm  ±è¹üÁØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 16:00~16:15 Hypertension and Cerebral Small Vessel Disease  ÀÓÀ缺(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 16:15~16:30 New Evidence of Hypertension Control on Stroke  À¯ÁØ»ó(±¹¹Î°Ç°­º¸Çè°ø´Ü) 
Åä·Ð 08-07 Room B 16:30~16:45 Panel Discussion  °­ÁöÈÆ, ±èÁ¤¹Î, ÃÖ°­È£(¼­¿ïÀÇ´ë, Áß¾ÓÀÇ´ë, Àü³²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 15:30~15:45 Proper BP Measurement Technique for BP Variability  Á¤¿ì¹é(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 15:45~16:00 BP Variability in Elderly Hypertensive Patients  ÃÖ¼ºÀÏ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 16:00~16:15 BP Variability in Stroke and Cognitive Decline  ±èÇзÉ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 16:15~16:30 Therapeutic Management for Patients with BP Variability  ÁøÁ¤¿¬(ÁøÁ¤¿¬) 
Åä·Ð 08-07 Room C 16:30~16:45 Panel Discussion  ¹Ú»ó¹Î, ¹Ú¿ëÇö, Á¶ÀºÁ¤(À»ÁöÀÇ´ë, ºÎ»êÀÇ´ë, ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 16:45~17:00 SGLT2 Inhibitor and Blood Pressure in CKD  À¯ÅÂÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 17:00~17:15 Neprilysin Inhibitors and Blood Pressure in CKD  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 17:15~17:30 CCB and Renoprotection in CKD  ±èÈ¿Áø(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room A 17:30~17:45 Beta Blocker and Renoprotection in CKD  ¹éÁøÇõ(°è¸íÀÇ´ë) 
Åä·Ð 08-07 Room A 17:45~18:00 Panel Discussion  ±è¼ö¿Ï, À¯°æµ·, À̵¿¿ø(Àü³²ÀÇ´ë, ¿ï»êÀÇ´ë, ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 16:45~17:00 Pro –±èÇöÁø(ÇѾçÀÇ´ë)  ±èÇöÁø(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 17:00~17:15 Cons – ±è´ëÈñ(¿ï»êÀÇ´ë)  ±è´ëÈñ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 17:15~17:30 Rebuttal Pro – ¹Ú¿ëÇö(ºÎ»êÀÇ´ë)  ¹Ú¿ëÇö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 08-07 Room B 17:30~17:45 Rebuttal Cons - Á¤Çý¹®(°æÈñÀÇ´ë)  Á¤Çý¹®(°æÈñÀÇ´ë) 
Åä·Ð 08-07 Room B 17:45~18:00 Panel Discussion ±è±âÇö(¿ï»êÀÇ´ë), Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë), Á¶ÀÎÁ¤(ÀÌÈ­ÀÇ´ë)  ±è±âÇö, Á¤¹ÌÇâ, Á¶ÀÎÁ¤(¿ï»êÀÇ´ë, ÇѸ²ÀÇ´ë, ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 16:45~17:00 Epidemiology of Prehypertension in Korea - Hyeon Chang Kim_±èÇöâ(Yonsei Univ.) [Eng]  ±èÇöâ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 08-07 Room C 17:00~17:15 National Governmental Policy to Enhance HT Control in Malaysia -Abdul Rashid Rahman (Malaysia) [Eng]  Abdul Rashid Rahman(Malaysia) 
±³À°½Ã°£ 08-07 Room C 17:15~17:30 Optimal Management Strategy in Prehypertension - Sang Hyun Ihm_ÀÓ»óÇö(Catholic Univ) [Eng]  ÀÓ»óÇö(Catholic Univ) 
±³À°½Ã°£ 08-07 Room C 17:30~17:45 Lifestyle Modification in Prehypertension - Yook Chin Chia(Malaysia) [Eng]  Yook Chin Chia(Malaysia) 
Åä·Ð 08-07 Room C 17:45~18:00 Panel Discussion  ¹Ú¼ºÇÏ, ¼º±âö, Abdul Rashid Rahman(¿¬¼¼ÀÇ´ë, ¼º±Õ°üÀÇ´ë, Malaysia) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦ 52ȸ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Ãá°è±¹Á¦Çмú´ëȸ : 2020-08-07""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2020³âµµ ´ëÇÑÀ̽ÄÇÐȸ Á¦16Â÷ Ãá°èÇмú´ëȸ(¿Â¶óÀÎ) : 2020-08-07
´ÙÀ½±Û 2020³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Çϰ迬¼ö±³À° : 2020-08-07
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20620 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼­¿ï¾Æ»êº´¿ø ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-30 0 64 2024-04-30
20619 °æ³² »ï¼ºÃ¢¿øº´¿ø (¿Â¶óÀÎ)»ï¼ºÃ¢¿ø Ambulatory Pediatrics 2024 : 2024-06-29 0 51 2024-04-30
20618 °æºÏ Á¦8Â÷ ´ëÇѸðüžÆÀÇÇÐȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­ÁÂ(¿µ³²) : 2024-06-29 0 28 2024-04-30
20617 ¼­¿ï °Ç±¹´ëÇб³º´¿ø 2024 KUMC Precision Medicine Lung Cancer Conference : 2024-06-28 0 20 2024-04-30
20616 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ ÀûÇ÷±¸Áúȯ¿¬±¸ ½ÉÆ÷Áö¾ö : 2024-06-28 0 29 2024-04-30
20615 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚÇÑ µÎ°æºÎ¾Ï ȯÀÚÀÇ Ä¡·á ¹× °æ°ú : 2024-06-27 0 24 2024-04-30
20614 ¼­¿ï 2024³â ´ëÇÑÈäºÎ¿µ»óÀÇÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 23 2024-04-30
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 33 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 38 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 32 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 35 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 28 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 35 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 26 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 21 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷